The long lineup of new biotech deals we’re seeing today continues in the Protocols section, with more pacts from Sarepta and bluebird.
Shares of Catabasis rocketed up 56% this morning on news of a new partnership. Fresh from winning the year’s most controversial FDA approval, Sarepta $SRPT is partnering with Catabasis on a combo drug for Duchenne muscular dystrophy. Catabasis $CATB will pair its preclinical oral NF-kB inhibition program with one of Sarepta’s exon-skipping programs.
Germany’s Medigene bagged a $15 million upfront and added R&D funding to collaborate with bluebird bio on some new TCR programs. Medigene will use its platform tech to generate T cell receptor (TCR) therapeutic candidates against four targets selected by bluebird. They’ll work together on the preclinical effort, with bluebird stepping up for any of the clinical work to follow. If it all works out perfectly, Medigene can score milestones worth more than a billion dollars.
Evidence of liver toxicity forced Alnylam $ALNY to scrap an early-stage program for ALN-AAT, an investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease. The Cambridge, MA-based biotech says that it will now add a replacement therapy to the pipeline.
Germany’s Boehringer Ingelheim will work with investigators at Sarah Cannon Research Institute on its cancer drug pipeline effort. They’ll be focused on combination efforts for BI 754091(anti- PD-1) and BI 754111 (anti-LAG 3).
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription